Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

BACKGROUND: Baricitinib was efficacious in a 24-week phase III study in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying anti rheumatic drugs (DMARDs) (csDMARDs) (RA-BUILD). OBJECTIVES: To evaluate radiographic progression of structural j...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Desirée, Dougados, Maxime, Chen, Ying-Chou, Greenwald, Maria, Drescher, Edit, Klar, Rena, Xie, Li, de la Torre, Inmaculada, Rooney, Terence P, Witt, Sarah L, Schlichting, Douglas E, de Bono, Stephanie, Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950651/
https://www.ncbi.nlm.nih.gov/pubmed/29765703
http://dx.doi.org/10.1136/rmdopen-2018-000662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950651/
https://www.ncbi.nlm.nih.gov/pubmed/29765703
http://dx.doi.org/10.1136/rmdopen-2018-000662

Ejemplares similares